B Cells | CHOP Research Institute

Can the NAD Metabolite Explain Why Lymphocytes Demonstrate Varied Immune Responses?

Published on

Mar 18, 2024

Metabolite Explains Differences in Immune Responses

Learn how the NAD metabolite controls how well T and B cells can detect their antigens, leading to quicker immune responses.

CHOP Researchers Elucidate Mechanism Behind Immunotherapy Resistance in B-ALL

Published on

Jan 24, 2022

in Cornerstone Blog

Researchers Find Mechanism of Treatment Resistance in B-ALL

Researchers identified aberrant splicing as a culprit behind treatment resistance in B-ALL.

Will Bailis, PhD

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

E-mail:

bailisw [at] chop.edu

Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

KTE-X19

This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

Humanized CART19 Phase 2 Trial

This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

Bailis Laboratory

All biological processes operate under biochemical constraints. The Bailis Lab aims to understand how metabolism controls the development and functional differentiation of the hematopoietic system by setting the biochemical potential of cells and tissues, using in vitro and in vivo CRISPR screening in primary immune cells.